Multiple Assemblies exist for SMTL entry 5tq3
Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin; X-RAY DIFFRACTION 2.69 Å

SMTL ID
5tq3.1
Ligands
4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol
Polypeptides
Tyrosine-protein kinase JAK2
Oligo-state
monomer
SMTL ID
5tq3.2
Ligands
4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol
Polypeptides
Tyrosine-protein kinase JAK2
Oligo-state
monomer